This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B22.2 (HIV disease resulting in wasting syndrome) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | Slim disease; HIV disease resulting in growth failure; HIV wasting syndrome; HIV-associated wasting; AIDS wasting syndrome |
| C. Adult onset | Likelihood of onset in adulthood: Very high — HIV wasting syndrome occurs as an AIDS-defining illness in adults with untreated or inadequately treated HIV infection. It is most common especially at the stage when the CD4+ T-cell count is markedly reduced (CD4 <200/μL), and before the spread of ART it was recorded as an AIDS-defining illness in about 18% of patients with AIDS. |
| 1. History | First described in East Africa in 1985 as 'Slim disease'. Included in AIDS-defining illnesses by the CDC in 1987. Official CDC definition of wasting syndrome in 1993: unintentional weight loss of 10% or more + chronic diarrhea or fever for 30 days or more. |
| 2. Causes | Wasting promoted by HIV-associated metabolic abnormalities, reduced dietary intake, malabsorption, and chronic infection or tumor. Increased catabolism due to inflammatory cytokines (TNF-α, IL-6, IL-1). Accelerated muscle protein breakdown. |
| 3. Genetics | Not a hereditary disease. TNF-α promoter polymorphism (-308G/A) influences the intensity of inflammation and the risk of wasting. IL-6 and IL-1β polymorphisms are related to susceptibility to wasting. |
| 4. General epidemiology | Recorded as the first AIDS-defining illness in about 18% of patients with AIDS before ART. A leading cause of death in persons with HIV in Africa. Prevalence has decreased by 90% in high-income countries since ART. Still an important complication in low-income countries. |
| 5. Pathophysiology | Combined mechanism: reduced energy intake (oral lesions, anorexia) + malabsorption (intestinal damage, chronic diarrhea) + increased catabolism (cytokines). Muscle atrophy (sarcopenia), fat loss, and protein loss → abnormal body composition → functional impairment. |
| 6. Symptoms | Unintentional weight loss (10% or more of baseline weight), severe asthenia and fatigue, persistent fever (30 days or more), chronic diarrhea (30 days or more). Muscle loss, decreased adipose tissue, anorexia, nausea. |
| 7. Signs | Marked weight loss, decreased muscle mass (decreased mid-upper arm muscle circumference), decreased subcutaneous fat, skin dystrophy. Decreased serum albumin and prealbumin, body mass index (BMI) below 18.5, limb muscle loss (dual-energy X-ray absorptiometry, DEXA). |
| 8. Screening | Regular weight measurement and BMI assessment in all persons with HIV. Body composition analysis (DEXA or bioelectrical impedance). Assessment of nutritional status (serum albumin, prealbumin, transferrin). Screening for infections causing diarrhea and fever. |
| 9. Diagnosis | CDC 1993 criteria: HIV infection + unintentional weight loss ≥10% + (chronic diarrhea ≥30 days or chronic weakness/fever ≥30 days, other diseases excluded). Nutritional assessment, body composition measurement, exclusion of opportunistic infection and malignancy. |
| 10. Treatment | Early initiation of ART is key. Nutritional support (oral and enteral nutrition supplementation). Appetite stimulants (megestrol acetate, dronabinol). Anabolic steroids (testosterone, nandrolone). Growth hormone (GH) administration. Treatment of underlying opportunistic infection. |
| 11. Prognosis | Weight recovery is possible in patients who respond to ART. Weight loss of 10-20% increases the risk of death 2- to 6-fold. When the catabolic state improves with ART, recovery of muscle mass is slow. Persistent wasting is a poor prognostic indicator. |
| 12. Prevention | Prevent immunosuppression through early HIV diagnosis and ART. Regular nutritional assessment. Concurrent exercise (resistance exercise). Block factors that cause wasting, such as diarrhea and fever, by preventing opportunistic infection. |
| 13. References | Includes 10 key references |
HIV-associated wasting syndrome was first described in East Africa (Uganda, Tanzania) in 1985 as a clinical syndrome characterized by extreme weight loss and chronic diarrhea. Local residents called this condition Slim disease, meaning "wasting away," and the term later became established across Africa as a representative clinical expression of AIDS.
In 1987, the US CDC revised its AIDS surveillance system and formally included HIV wasting syndrome as an AIDS-defining illness. This acknowledged that weight loss and chronic systemic illness are important as independent complications of AIDS. Initially the cause of wasting was understood merely as a secondary phenomenon due to undernutrition or opportunistic infection, but subsequent research elucidated the metabolic effects of HIV itself and the role of inflammatory cytokines.
In 1993, the CDC established the official definition of HIV wasting syndrome: in a patient with HIV infection, (1) unintentional weight loss of 10% or more of baseline weight, (2) chronic diarrhea (2 or more times per day, for 30 days or more) or chronic weakness and fever (30 days or more, intermittent or persistent), and (3) not explained by another disease (infection, tumor, etc.). These criteria are still used today as the diagnostic criteria for wasting syndrome by the CDC and WHO.
After the introduction of ART in the late 1990s, the incidence of HIV wasting syndrome fell dramatically in high-income countries. However, a phenomenon of persistent low-grade weight loss and sarcopenia despite ART was observed, raising a new clinical challenge termed "wasting syndrome in the ART era." In addition, ART-related metabolic complications (lipodystrophy, insulin resistance) complicated the pattern of wasting syndrome.
Since the 2000s, wasting syndrome has been reconsidered as a complex syndrome that goes beyond simple weight loss to include decreased muscle mass (sarcopenia), functional decline, and reduced quality of life. In particular, sarcopenic obesity is increasing in older persons with HIV on ART, highlighting the importance of body composition assessment.
HIV wasting syndrome is the result of combined mechanisms rather than a single cause. It is broadly explained along three axes: reduced energy intake, nutrient malabsorption, and increased catabolic processes.
Reduced energy intake: Anorexia due to HIV infection is a major contributing factor. The HIV Tat protein disturbs signaling of appetite-regulating hormones (leptin, ghrelin) in the hypothalamus. Opportunistic infections of the mouth (candidiasis, herpes), esophageal ulcers, and nausea and vomiting interfere with oral intake. Severe depression, neurocognitive impairment, and drug adverse effects also contribute to reduced dietary intake.
Malabsorption: HIV directly damages the small intestinal mucosa, reducing nutrient absorption. Loss of CD4+ intestinal lymphocytes (lamina propria CD4+ T cells) reduces intestinal immunity, and chronic diarrhea due to opportunistic infection (Cryptosporidium, cytomegalovirus, Mycobacterium, etc.) worsens malabsorption. Loss of intestinal epithelial cells, villous atrophy, and increased intestinal permeability are characteristic pathologic findings.
Increased catabolism: The chronic inflammatory state caused by HIV infection increases catabolic metabolism. TNF-α (cachectin) promotes lipolysis in adipose tissue and induces muscle protein breakdown. IL-6 and IL-1β increase acute-phase protein synthesis in the liver and suppress anabolic protein synthesis. The increase in basal metabolic rate observed in chronic HIV infection also makes the energy balance negative.
Hormonal abnormalities: A hormonal imbalance in persons with HIV, with decreased testosterone, growth hormone (GH), and IGF-1 levels and increased cortisol levels, promotes wasting. Secondary hypogonadism is common in men with HIV and accelerates muscle catabolism. Adrenal dysfunction and hypothyroidism are also factors that cause wasting.
HIV wasting syndrome is not a hereditary disease, but host genetic polymorphisms influence susceptibility to and severity of wasting.
TNF-α promoter polymorphism: The G/A polymorphism at position -308 of the TNF-α promoter (rs1800629) is a major polymorphism that determines the level of TNF-α expression. Carriers of the -308A allele are reported to have higher TNF-α expression, with increased intensity of inflammation and an increased risk and severity of wasting in HIV infection. The distribution of this polymorphism in African populations may contribute to regional differences in wasting syndrome.
IL-6 polymorphism: The IL-6 promoter -174G/C polymorphism (rs1800795) influences IL-6 expression. The -174C allele can increase IL-6 expression and promote chronic inflammation and increased catabolism. An association between this polymorphism and the risk of weight loss has been reported in persons with HIV.
Appetite-regulating genes: Leptin receptor (LEPR) gene polymorphisms affect leptin signaling and are involved in appetite regulation and energy metabolism. Melanocortin-4 receptor (MC4R) polymorphisms affect the appetite-suppressing pathway. Disturbance of the appetite-suppressing pathway by HIV Tat may interact with these genetic variants to determine the severity of wasting.
Genes related to muscle metabolism: Variants of the myostatin (MSTN) gene are directly involved in regulating muscle mass. Carriers of myostatin-inhibiting gene variants may lose less muscle mass in HIV-associated wasting. Polymorphisms in the IGF-1 (insulin-like growth factor-1) receptor and signaling pathway also affect susceptibility to HIV-associated sarcopenia.
The epidemiology of HIV wasting syndrome is sharply divided before and after the introduction of ART, with large disparities by region and economic level.
Epidemiology before ART: Using the 1993 CDC definition, wasting syndrome was reported as the first AIDS-defining illness in about 18% of patients with AIDS in the US. In European cohort studies, the cumulative incidence of wasting syndrome among patients with AIDS reached about 40-60%. In sub-Saharan Africa, the incidence of "Slim disease" in persons with HIV was very high, observed in more than 50% of persons with HIV in some areas.
Epidemiology after ART: After the introduction of ART, the incidence of HIV wasting syndrome decreased by more than 90% in high-income countries. However, even among persons with HIV on ART, 5-20% maintain persistent weight loss or low body weight. It is currently estimated that about 14% of persons with HIV worldwide experience weight loss at the level of wasting syndrome despite ART.
Situation in low-income countries: In sub-Saharan Africa, wasting syndrome is still one of the leading causes of death in persons with HIV with limited access to ART. According to WHO reports, wasting and malnutrition account for 30-40% of causes of death in persons with HIV in low-income countries. Tuberculosis co-infection acts as a major accelerating factor for wasting syndrome.
Risk factors: CD4+ T cells <200/μL, HIV RNA >100,000 copies/mL, untreated with ART, accompanying opportunistic infection, chronic diarrhea, alcohol and drug abuse, and socioeconomic vulnerability (poverty, food insecurity) are independent risk factors for wasting syndrome.
The pathophysiology of HIV wasting syndrome is a process in which reduced energy intake, malabsorption, and increased catabolic metabolism act in combination.
Collapse of intestinal immunity and malabsorption: From the early stage of infection, HIV rapidly depletes CD4+ T lymphocytes (especially CCR5+ Th17 cells) of the intestinal lamina propria. As a result, intestinal mucosal immunity collapses and bacterial translocation increases. Small intestinal opportunistic infections (Cryptosporidium, microsporidia, CMV enteritis) occur, causing chronic diarrhea and malabsorption. Increased apoptosis of intestinal epithelial cells, villous atrophy, and increased intestinal permeability reduce nutrient absorption.
Cytokine-mediated catabolism: TNF-α, continuously secreted in HIV infection, increases the activity of lipolytic enzymes of adipose tissue (HSL, adipose triglyceride lipase), promoting fat breakdown. TNF-α and IL-1β activate the ubiquitin-proteasome pathway in muscle cells to degrade muscle protein. IL-6 suppresses hepatic synthesis of negative acute-phase proteins (albumin, prealbumin).
Hormonal catabolic imbalance: In persons with HIV, testosterone levels fall to 30-50% of those in normal men. Decreased testosterone reduces muscle protein synthesis and worsens lipolysis and fat redistribution. Growth hormone (GH) secretion increases but peripheral resistance increases, so IGF-1 production decreases. This GH resistance creates an abnormal coexistence of muscle catabolism and fat accumulation (lipodystrophy).
Mitochondrial dysfunction: The HIV Vpr protein disturbs the mitochondrial membrane potential, reducing energy production in muscle cells. Nucleoside reverse transcriptase inhibitors (NRTIs) inhibit mitochondrial DNA polymerase γ, causing mitochondrial dysfunction, which worsens muscle wasting and lipodystrophy.
The clinical symptoms of HIV wasting syndrome center on the three main elements of the CDC 1993 criteria (weight loss, chronic diarrhea, chronic fever/weakness).
Weight loss: The most characteristic and essential symptom. Unintentional weight loss of 10% or more of baseline weight is required for diagnosis. Early on, loss of adipose tissue predominates, and with progression loss of muscle mass (sarcopenia) becomes prominent. In severe cases an extreme wasting state is reached, with loss of 30-50% of body weight. Weight loss is the result of the combined action of reduced dietary intake and increased catabolism.
Chronic diarrhea: Chronic diarrhea occurring 2 or more times per day and lasting 30 days or more is one of the diagnostic criteria. Causes are opportunistic infection (Cryptosporidium, CMV, microsporidia), direct HIV intestinal damage, and drug adverse effects. Massive fluid and electrolyte loss worsens nutritional status. Even in the absence of diarrhea, chronic weakness and fever meet the diagnostic criteria.
Chronic fever and weakness: Characterized by chronic fever of unknown cause (body temperature 38℃ or higher, intermittent or persistent, 30 days or more) and extreme systemic fatigue. The fever is due to HIV itself or to opportunistic infection (MAC, CMV, PCP, etc.). Functional capacity is markedly reduced, and weakness at a level that makes self-care difficult appears.
Other symptoms: Anorexia, nausea, xerostomia, taste changes, depression, and anxiety accompany. Increased risk of falls and decreased activity due to muscle weakness. Night sweats and cognitive decline often accompany.
Anthropometric findings: Underweight with body mass index (BMI) below 18.5 kg/m². Decreased mid-upper arm circumference (MUAC) reflects loss of muscle mass. Decreased triceps skinfold thickness confirms loss of subcutaneous fat. On dual-energy X-ray absorptiometry (DEXA), decreased appendicular lean mass index and decreased body fat mass.
Blood and biochemical findings: Decreased serum albumin (below 3.5 g/dL) and decreased prealbumin (transthyretin) reflect short-term deterioration of nutritional status. Decreased serum transferrin and binding globulin (haptoglobin). Decreased total lymphocyte count, markedly decreased CD4+ T-cell count. Elevated blood TNF-α and IL-6 levels reflect the catabolic state. Iron-deficiency anemia or anemia of chronic disease. Trace element deficiencies such as magnesium, zinc, and selenium are common.
Endocrine findings: Decreased serum total and free testosterone (below the lower limit of normal). Decreased IGF-1, increased GH (GH resistance pattern). Decreased serum DHEA-S. Thyroid dysfunction (low T3 syndrome or overt hypothyroidism).
Functional findings: Decreased grip strength is a clinical indicator of sarcopenia. Decreased exercise endurance on the 6-minute walk test. Functional decline with Karnofsky Performance Status below 70.
Screening for wasting syndrome in persons with HIV should be performed systematically at every outpatient visit.
Regular weight measurement: Measure weight at every visit in all persons with HIV and compare it with previous records. If there is unintentional weight loss of 5% or more within 6 months or 10% or more within 12 months, begin an in-depth evaluation. If BMI is below 18.5, perform a nutritional assessment immediately.
Body composition assessment: Quantify muscle mass, fat mass, and body water with bioelectrical impedance analysis (BIA) or DEXA. Check whether the patient meets the sarcopenia criteria (men: appendicular lean mass index below 7.0 kg/m², women: below 5.5 kg/m²). Assess functional muscle strength by hand grip dynamometry.
Nutritional status assessment: Measure serum albumin, prealbumin, and transferrin. Assess energy and protein intake with a 24-hour dietary recall or dietary intake record. Perform Nutritional Risk Screening 2002 (NRS-2002) regularly.
Search for related causes: If chronic diarrhea is present, perform stool tests (ova and parasites, C. difficile, CMV) and colonoscopy. If fever is present, perform blood culture, MAC PCR, and CMV pp65 antigenemia testing. Screen for hormonal abnormalities by measuring testosterone and IGF-1.
Diagnosis of HIV wasting syndrome is based on the official CDC 1993 criteria, and a thorough differential diagnosis must be carried out together.
CDC 1993 diagnostic criteria: All of the following 3 conditions must be met. (1) Confirmed HIV infection (positive HIV antibody or PCR). (2) Unintentional weight loss: 10% or more of baseline weight. (3) One of the following: (a) chronic diarrhea — loose stools 2 or more times per day, lasting 30 days or more; or (b) chronic weakness and fever — intermittent or persistent fever (body temperature 38.0℃ or higher), lasting 30 days or more. The weight loss must not be explained by other causes (malignancy, malabsorption syndrome, systemic infection, etc.).
Differential diagnosis: HIV wasting syndrome must be differentiated from other AIDS complications that cause weight loss, fever, and diarrhea. Conditions to differentiate: (1) opportunistic infections (PCP, MAC, CMV colitis, cryptosporidiosis, toxoplasmosis), (2) AIDS-related malignancies (lymphoma, Kaposi sarcoma), (3) drug adverse effects (ART-related gastrointestinal toxicity), (4) endocrine disease (adrenal insufficiency, hypothyroidism). Appropriate testing for each cause is needed.
Quantifying nutritional status: Review previous weight records to confirm loss of 10% or more of baseline weight. Quantify the absolute decrease in muscle mass and fat mass by body composition analysis with DEXA. Classify the severity of malnutrition by measuring serum nutritional indicators (albumin, prealbumin, transferrin) (mild: albumin 3.0-3.5 g/dL; moderate: 2.5-3.0; severe: <2.5).
Assessment of hormonal abnormalities: Measure serum total testosterone (blood drawn early in the morning at 8 a.m.), free testosterone (or sex hormone-binding globulin, SHBG), LH, and FSH. Exclude secondary causes (hypopituitarism, drug effects) in men with hypotestosteronism. Assess the GH-IGF-1 axis by measuring insulin-like growth factor-1 (IGF-1) and IGFBP-3.
Treatment of HIV wasting syndrome is based on HIV suppression by ART and comprehensively applies nutritional support, appetite stimulation, anabolic therapy, and treatment of underlying causes.
Antiretroviral therapy (ART): Initiation and optimization of ART is the foundation of wasting syndrome treatment. HIV RNA suppression and CD4 recovery by ART reduce cytokine-mediated increased catabolism and restore intestinal immunity, improving malabsorption. In most patients with mild to moderate wasting syndrome, weight and nutritional status improve within 6-12 months with ART alone.
Nutritional support: Active nutritional counseling and dietary supplementation are needed to meet energy requirements. Energy target: 35-40 kcal/kg/day; protein target: 1.5-2.0 g/kg/day. If oral intake is insufficient, add oral nutritional supplements (ONS). If intestinal malabsorption is severe, consider enteral (nasogastric/gastrostomy) or parenteral nutrition. Replace deficiencies of trace elements (zinc, selenium, vitamin D, B12).
Appetite stimulants: Megestrol acetate 800 mg/day: increases appetite and weight, but mainly as fat gain, and has the adverse effect of adrenal suppression. Dronabinol (synthetic cannabinoid) 2.5 mg twice daily: stimulates appetite and reduces nausea. Mirtazapine: can be expected to promote appetite and have an antidepressant effect at the same time.
Anabolic therapy: Testosterone replacement therapy (intramuscular injection or gel application) in men with testosterone deficiency. Administration of testosterone above the physiologic dose to increase muscle mass has also been studied in men with normal testosterone. Nandrolone decanoate (200 mg intramuscularly every 2 weeks) is effective for increasing muscle mass but requires monitoring of hepatotoxicity. Oxandrolone (an oral anabolic steroid) is used in some patients.
Growth hormone: Recombinant human growth hormone (somatropin) 4-6 mg/day subcutaneously has FDA approval for HIV wasting syndrome. It increases weight and muscle mass but is costly and has adverse effects (arthralgia, edema, hyperglycemia). At present ART takes priority, and growth hormone is applied selectively.
Treatment of underlying causes: Treat opportunistic infections that cause chronic diarrhea (Cryptosporidium, CMV, MAC) with their respective standard treatments. Improve hormonal imbalance with testosterone replacement, treatment of hypothyroidism, and correction of adrenal insufficiency. A resistance exercise program (3 or more times per week) is essential for recovery of muscle mass and function.
The prognosis of HIV wasting syndrome has improved considerably since the introduction of ART, but varies according to the severity and cause of wasting.
Weight loss and risk of death: A 10% loss of baseline weight doubles the risk of death from AIDS, and a 20% loss is associated with a 6-fold increase. When body weight falls below 66% of ideal body weight, the risk of death rises dramatically. Loss of muscle mass (lean body mass) is more important than fat loss for predicting prognosis.
Response to ART: Weight recovery is observed in about 70-80% of patients who respond to ART (undetectable HIV RNA). However, recovery of muscle mass is slower than recovery of fat mass, and normalization of body composition may be delayed for 1-2 years after ART. In patients refractory to ART (resistant virus or poor adherence), wasting continues to progress.
Long-term complications: Despite weight recovery after ART treatment, abnormalities of body composition (lipodystrophy, sarcopenic obesity) may persist. Chronic sarcopenia is associated with increased fall risk, increased cardiovascular risk, and reduced quality of life. If adrenal insufficiency and hypothyroidism are not corrected, wasting persists.
Early ART: Start ART immediately after early HIV diagnosis to prevent immunosuppression and the catabolic state. The higher the CD4+ T-cell count at which ART is started, the lower the risk of developing wasting syndrome. Maintaining ART adherence is key to long-term prevention of wasting.
Regular nutritional monitoring: Weigh and assess BMI at every visit. Perform nutritional risk screening (NRS-2002) regularly to detect early malnutrition. Educate patients through dietary counseling to maintain adequate energy and protein intake.
Prevention of opportunistic infection: PCP prophylaxis with TMP-SMX at CD4+ T cells <200/μL. MAC prophylaxis with azithromycin or clarithromycin at CD4 <50/μL. Consider prophylactic treatment for CMV retinitis. Block factors that cause wasting, such as diarrhea and fever, through prevention of opportunistic infection.
Exercise and lifestyle: Resistance exercise (3 times per week, 8-12 repetitions) is effective for maintaining muscle mass. Aerobic exercise maintains cardiopulmonary function and overall physical fitness. Smoking cessation and abstinence from alcohol reduce behavioral risk factors that worsen HIV-associated malnutrition and wasting.
Food security: In persons with HIV in low-income countries, food insecurity is a major determinant of wasting syndrome. It is reported that a structural approach linking food assistance programs with ART is effective in preventing HIV wasting syndrome in Africa.